Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Valbenazine · Ingrezza, NBI-98854

Small molecule · Inhibitor of vesicular monoamine transporter 2 (SLC18A2) · developed by Neurocrine

Approved FDA, Apr 2017

NBIX Developer

2 Registered trials

What is Valbenazine?

Valbenazine is a small-molecule VMAT2 inhibitor that reversibly blocks vesicular monoamine transporter 2, reducing monoamine uptake into synaptic vesicles.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Ingrezza, NBI-98854
Drug type: Small molecule
Targets: vesicular monoamine transporter 2 (SLC18A2)
Mechanism: Inhibitor of vesicular monoamine transporter 2 (SLC18A2)
Pathways: monoamine storage and release
Therapy area: Neurology
Developer: Neurocrine (NBIX)
FDA status: Approved as Ingrezza (April 11, 2017), NDA209241 · FDA label

✅ FDA-approved uses

Tardive dyskinesia
Chorea associated with Huntington's disease

From the indications section of the FDA label (version of Apr 17, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07105111	Phase 4	Schizophrenia	Recruiting	NBIX
NCT06107829	Phase 4	Tardive Dyskinesia	Withdrawn	NBIX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Bipolar DisorderMajor Depressive DisorderSchizoaffective DisorderSchizophreniaDevelopmental DisabilitiesIntellectual DisabilityTardive Dyskinesia

More from Neurocrine

Crinecerfont FDA approved Chronocort Phase 3 DITEST Phase 1 Luvadaxistat Phase 2 NBI-1065845 Phase 3 NBI-1065890 Phase 2 NBI-1070770 Phase 2 NBI-1117567 Phase 2 NBI-1117568 Phase 3 NBI-1117570 Phase 2 NBI-827104 Phase 2 NBI-921352 Phase 2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the NBIX page.

Follow NBIX, the company behind Valbenazine

See NBIX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NBIX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z